ArticleAdvances in therapy2026
Uncontrolled Hypertension Prevalence, Characteristic Profiles, and Risk of Cardiorenal and Metabolic Outcomes: Insights from the EnligHTN Study.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antihypertensive Medication Patterns in Patients with Hypertension that is Harder to Control: Insights from the EnligHTN Study.Advances in therapy · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBlood pressure (BP) control often remains suboptimal despite patients receiving multiple antihypertensives. Recent clinical trials of novel antihypertensives have included patients with hypertension receiving ≥ 2 antihypertensives; however, evidence of hypertension prevalence, patient characteristics, and adverse outcomes risk in this population are limited. This study aimed to assess the prevalence of uncontrolled (uHTN) and controlled hypertension (cHTN) in patients receiving ≥ 2 antihypertensives and to describe patient characteristics and adverse outcomes risk.
methodsEnligHTN is a multinational, observational, longitudinal, cohort study of adults with hypertension. Data from 2018 to 2023 were extracted from electronic medical records and claims data sources from the US, UK, Spain, Germany, and Israel. Adults with a hypertension diagnosis after 2018 and a BP measurement after receiving ≥ 2 antihypertensives for ≥ 30 days (index date) were included. uHTN was defined based on index BP according to national guidelines (US: ≥ 130/80 mmHg; other countries: ≥ 140/90 mmHg). Data were summarized by country.
resultsOverall, data from ~ 340,000 patients were included. Across countries, mean age of patients was 57‒70 years, 50-63% were male, and 37-50% were female. The proportion of patients with uHTN versus cHTN was: 69.4% versus 30.6% (US), 74.8% versus 25.2% (UK), 53.2% versus 46.8% (Germany), 47.3% versus 52.7% (Spain), and 32.5% versus 67.5% (Israel), respectively. Dyslipidemia, type 2 diabetes, and renal disease were common comorbidities across all countries. Prevalence of obesity ranged from 20-63% (uHTN) and 18-53% (cHTN). uHTN was associated with significantly higher rates of transient ischemic attacks, stroke, myocardial infarction, end-stage renal disease, and type 2 diabetes versus cHTN.
conclusionsDespite widespread availability of multiple antihypertensives, BP control remains suboptimal across diverse healthcare systems in multiple countries, with uHTN associated with increased risk of adverse cardiorenal and metabolic outcomes. Enhanced hypertension management strategies are urgently needed to reduce the burden of uHTN. Graphical abstract available for this article.
Indexed as
Identifiers
42440039What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.